Prelude Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Welcome, everyone. It is Josh Schimmer from the Evercore ISI biotech team. Pleased to introduce Prelude Therapeutics.
Questions & Answers
Kris, give us a quick snapshot of Prelude and what you have going on there.
Great. Sure, Josh, thanks. Thank you very much for the opportunity to participate in the fireside. Joining with me today is our Chief Scientific Officer, Peggy Scherle; and our Chief Financial Officer, Laurent Chardonnet. So we are excited to participate in this meeting. And for those of you in the audience that are new to Prelude's story, we are a clinical stage precision oncology company with a pipeline of novel compounds targeting validated pathways in cancer, all internally discovered.
We were founded in 2016 with a vision of building a precision oncology company from scratch -- a fully integrated company. And since our inception, we've been focused on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |